|3-(苯并[d][1,3]二氧杂环戊烯-5-基)-5-(3-溴苯基)-1H-吡唑|CsnPharm

CAS No.: 882697-00-9

Emrusolmin Catalog No. CSN24266

Synonyms: Anle138b

Anle138b is an oligomeric aggregation inhibitor which can block the formation of pathological aggregates of prion protein (PrP(Sc)) and of α-synuclein (α-syn) deposited in PD and other synucleinopathies such as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA).

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Anle138b ,the novel oligomer modulator, is an inhibitor of α-synuclein (α-syn) and prion-protein (PrPSc) aggregation that reduces the progression of prion and Parkinson′s disease in animal models. In vitro, anle138b blocked the formation of pathological aggregates of PrPSc and α-syn, which is deposited in PD and other synucleinopathies such as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). In mouse models of prion disease and PD mouse models, anle138b strongly inhibited oligomer accumulation, neuronal degeneration, and disease progression in vivo. ^[1] Anle138b is capable of prolonging the survival of prion-infected mice even after onset of symptoms, and anle138b started in the symptomatic disease phase at 50 weeks of life has a significant effect on survival until onset of terminal disease^[2].Anle138b showed structure-dependent binding to pathological aggregates and strongly inhibited formation of pathological oligomers^[1]. Anle138b strongly inhibited all prion strains including BSE-derived and human prions in a purely human system and had no detectable toxicity at therapeutic doses and an excellent oral bioavailability and blood–brain-barrier penetration , which indicated that this compound may also be useful for treatment of human prion disease^[1].
参考文献

[1] Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, Bähr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, Bötzel K, Groschup M, Kretzschmar H, Griesinger C, Giese A. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 2013 Jun;125(6):795-813. doi: 10.1007/s00401-013-1114-9. Epub 2013 Apr 19. PMID: 23604588; PMCID: PMC3661926.
[2] Levin J, Schmidt F, Boehm C, Prix C, Bötzel K, Ryazanov S, Leonov A, Griesinger C, Giese A. The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol. 2014 May;127(5):779-80. doi: 10.1007/s00401-014-1265-3. Epub 2014 Mar 11. PMID: 24615514; PMCID: PMC3984662.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.9140 mL
- 14.5698 mL
- 29.1397 mL
- 5 mM
- 0.5828 mL
- 2.9140 mL
- 5.8279 mL
- 10 mM
- 0.2914 mL
- 1.4570 mL
- 2.9140 mL

技术信息

CAS号

882697-00-9

储存条件

粉末: Keep in dark place,Inert atmosphere,Room temperature

液体: -20°C:3-6 月 -80°C:12月

分子式

C16H11BrN2O2

运输

蓝冰

分子量

343.17

别名

Anle138b

溶解度

DMSO	65.0 mg/mL (189.4 mM)
Water	insoluble

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

Emrusolmin Catalog No. CSN24266

靶点选择性

请登录您的专属账户

确认信息